Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study

Journal of Psychopharmacology
Silvio BellinoFilippo Bogetto

Abstract

Guidelines of the American Psychiatric Association for borderline personality disorder (BPD) indicate selective serotonin reuptake inhibitors and the serotonin and noradrenaline reuptake inhibitor (SNRI) venlafaxine for treating affective dysregulation and impulsive behavioural dyscontrol symptoms. The SNRI duloxetine has been studied in patients with major depression, generalized anxiety disorder and fibromyalgia, showing particular efficacy on somatic complaints. This study investigates duloxetine in the treatment of patients with BPD. Eighteen outpatients with a DSM-IV-TR diagnosis of BPD were treated with open-label duloxetine, 60 mg/day, for 12 weeks. Patients were assessed at baseline, week 4 and 12 with the CGI Severity item, the BPRS, the HAM-D, the HAM-A, the SOFAS, the BPD Severity Index (BPDSI) and the HSCL-90-Somatization Subscale (HSCL-90 SOM). Adverse effects were evaluated using the Dosage Record Treatment Emergent Symptom Scale. Statistics were performed with the analysis of variance. Significant P values were <or=0.05. Fourteen patients completed the study. Four patients (22.2%) discontinued treatment in the first 4 weeks because of non-compliance. A significant change was found for: BPRS, HAM-D, SOFAS, BPDSI t...Continue Reading

References

Sep 1, 1992·The American Journal of Psychiatry·H H GoldmanT R Lave
Feb 1, 1990·The American Journal of Psychiatry·M H TeicherJ O Cole
Jan 1, 1989·Progress in Neuro-psychopharmacology & Biological Psychiatry·M J Norden
Feb 1, 1995·Journal of Clinical Psychopharmacology·C SalzmanE Miyawaki
Dec 24, 1997·Archives of General Psychiatry·E F Coccaro, R J Kavoussi
Mar 24, 2000·The Psychiatric Clinics of North America·M A Oquendo, J J Mann
May 10, 2002·The Journal of Clinical Psychiatry·Michael J DetkeMark A Demitrack
Mar 28, 2003·Journal of Personality Disorders·Arnoud ArntzArthur J H T de Bie
Jan 1, 1959·The British Journal of Medical Psychology·M HAMILTON
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Jan 8, 2004·Psychosomatics·David J GoldsteinMark A Demitrack
Oct 27, 2004·Journal of Psychiatric Research·Stephen K BrannanAlan F Schatzberg
Jul 22, 2005·Depression and Anxiety·Robert M A HirschfeldMichael J Detke
Apr 15, 2006·Development and Psychopathology·Jackie K GollanEmil F Coccaro
May 13, 2006·Journal of Psychiatric Research·Xingqun NiJames L Kennedy
Sep 16, 2006·Depression and Anxiety·Henrik KesslerHarald C Traue
Sep 28, 2006·Depression and Anxiety·Chana B KorenblumRussell J Schachar
Feb 7, 2007·Current Opinion in Rheumatology·Daniel S Rooks
Apr 7, 2007·International Clinical Psychopharmacology·James HartfordJanelle Erickson
Apr 10, 2007·Psychiatric Genetics·Xingqun NiJames L Kennedy
Apr 24, 2007·Biological Psychiatry·Paul H SoloffWalter H Kaye
May 4, 2007·The Journal of Clinical Psychiatry·Jean EndicottRalph W Swindle
Jul 4, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Hannu KoponenJames M Russell
Jul 11, 2007·Depression and Anxiety·David L DunnerMadelaine Wohlreich
Oct 17, 2007·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Lesley M Arnold
Aug 30, 2007·BMC Psychiatry·James I HudsonMichael J Detke
Oct 16, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Madelaine M WohlreichJohn H Greist
Jan 22, 2008·Journal of Clinical Psychopharmacology·Joel RaskinCornelius Katona
Mar 18, 2008·Journal of Clinical Psychopharmacology·Frédérique Van den EyndeKurt Audenaert

❮ Previous
Next ❯

Citations

Dec 9, 2010·Current Psychiatry Reports·Louis Feurino, Kenneth R Silk
Nov 21, 2014·International Journal of Psychiatry in Clinical Practice·Randy A SansoneMichael W Wiederman
Apr 25, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·René BridlerWaldemar Greil
Nov 22, 2014·Current Psychiatry Reports·Jutta M Stoffers, Klaus Lieb
Nov 7, 2019·Expert Opinion on Pharmacotherapy·Paola BozzatelloSilvio Bellino
Aug 22, 2017·Frontiers in Psychiatry·Untara ShaikhSaeed Ahmed
Sep 30, 2020·The Psychiatric Quarterly·Anaïs MungoPhilippe Fontaine
Nov 22, 2019·Frontiers in Psychiatry·Maria Rosaria Anna MuscatelloAntonio Bruno

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.